•  
  •  
 

Henry Ford Hospital Medical Journal

Abstract

The role of immune mechanisms in the development and control of prostatic carcinoma appears to be complicated by the endocrine response of some tumors. The progression of endocrine-independent tumors is more directly related to host-immune response. Evaluation of the role of chemotherapeutic agents must include their effect on the host-immune response. The use of BCC in patients with metastatic prostatic carcinoma produces no alteration in cell-mediated immunity but produces local tumor necrosis. The use of nonspecific antigens to enhance host-immune response may be more effective when used as adjuvant therapy in earlier stages of prostatic adenocarcinoma.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.